GlassScriptPhysician profile
Brendan O'Hare
NPI 1669678116
$13,222.36
in general payments reported to CMS, 2019-2025
36 companies · $2,429 in 2025
The $2,429 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,635 · 2020: $1,173 · 2021: $1,738 · 2022: $2,325 · 2023: $1,799 · 2024: $2,124 · 2025: $2,429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,337 · Education: $14.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,337.04 |
| Education | $14.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,467.81 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,881.13 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $1,401.24 | 2019-2025 | Stelara, Tremfya, Simponi |
| Gilead Sciences, INC. | $1,334.71 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $723.60 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Qol Medical, LLC | $545.10 | 2019-2025 | Sucraid, Sucraid |
| Pfizer INC. | $332.18 | 2019-2025 | |
| Ardelyx, INC. | $261.58 | 2022-2025 | Ibsrela |
| Genzyme Corporation | $242.27 | 2022-2025 | |
| Evoke Pharma, INC. | $233.58 | 2022-2025 | Gimoti |
| Aimmune Therapeutics, INC. | $228.23 | 2024-2025 | Zenpep |
| Braintree Laboratories, INC. | $201.54 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $194.67 | 2022-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $162.78 | 2024-2025 | Voquezna |
| Concordia Pharmaceuticals INC. | $134.82 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $127.14 | 2025 | Rezdiffra |
| Intercept Pharmaceuticals, INC. | $85.26 | 2019-2022 | |
| Lilly USA, LLC | $77.79 | 2025 | Omvoh |
| Celltrion USA INC. | $73.72 | 2024-2025 | Vegzelma, Zymfentra |
| Ferring Pharmaceuticals INC. | $60.91 | 2020-2023 | Rebyota |
| Ipsen Biopharmaceuticals, INC | $59.47 | 2024-2025 | Iqirvo |
| Redhill Biopharma INC. | $57.47 | 2022 | |
| Merck Sharp & Dohme LLC | $49.87 | 2019-2023 | Dificid |
| Shire North American Group INC | $49.53 | 2019 | |
| Nestle Healthcare Nutrition INC. | $37.75 | 2021-2023 | |
| Ucb, INC. | $33.15 | 2019 | |
| Conmed Corporation | $21.92 | 2024 | Conmed Hemostasis |
| Allergan, INC. | $19.50 | 2019 | |
| Exact Sciences Corporation | $18.61 | 2024 | Cologuard Collection Kit |
| Janssen Scientific Affairs, LLC | $18.04 | 2019 | |
| Biocompatibles, INC. | $17.63 | 2019 | |
| Daiichi Sankyo INC. | $16.87 | 2019 | |
| Micro-Tech Endoscopy USA, INC. | $14.38 | 2025 | |
| Ironwood Pharmaceuticals, INC | $13.95 | 2019 | |
| Amgen INC. | $12.87 | 2022 | |
| Alfasigma USA, INC. | $11.29 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brendan O'Hare listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.